Recent Business Highlights

Highlights of FY18 Filings Good filings performance 19 ANDAS & 1 NDA filed in the USA Markets India Business performance post-GST picked up pace for the rest of FY18 Observations No critical observations in multiple regulatory inspections in CTOs. FTO2 and FTO3 cleared regulatory hurdles New markets in EM showed positive early performance trends PSAI service levels to customers started showing improvement towards end of the year Product launches Exciting new product launches in NAG like Sevelamer, Lipo Dox, Palonosetron Inj, OTC Levocetirizine Cost Control in the organization helped partially offset revenue challenges 10

View entire presentation